As Amgen gears up to launch osteoporosis candidate denosumab, a host of smaller players are working on what they see as the next-generation therapies: those that help build up new bone. Tough economic times across the board, plus the high development risks and costs associated with osteoporosis--a chronic, primary care condition--are making financing almost impossible for some.
By Melanie Senior
In a sense, it’s easy to see why most companies would want to steer away from trying to develop a...
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
AbbVie now expects the two Humira successors to bring in $25bn this year. On its Q2 earnings call, the firm also pointed to strength in neuroscience, with 24% growth.
François Roger believes fixing inefficiencies is more important than playing with pricing.
Cipla’s partnered filgrastim biosimilar is expected to debut in the US in Q2 FY26 and the Indian firm expects an investment return ratio for its biosimilar engine “not too far” from that of a complex generic product amid an enabling regulatory environment.
Celltrion is set to acquire a US biologics manufacturing facility that will "eliminate" its US tariff risks and provide a ready-made production base for future expansion.
Second quarter revenue and EPS beat consensus and BMS raised its 2025 revenue guidance, but after multiple recent Phase III failures, executives said the company is reviewing studies with near-term readouts.
AbbVie now expects the two Humira successors to bring in $25bn this year. On its Q2 earnings call, the firm also pointed to strength in neuroscience, with 24% growth.
Sales of Leqembi, Zurzuvae and Skyclarys contributed to Biogen’s sales and earnings guidance raise, positioning the company closer to potential growth.
